Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Inventiva Sa (IVA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Inventiva's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3.250 +0.090    +2.85%
26/04 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 24,637
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 3.060 - 3.275
Inventiva 3.250 +0.090 +2.85%

Inventiva Sa Company Profile

 
Get an in-depth profile of Inventiva Sa, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

117

Equity Type

ADR

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Contact Information

Address 50 rue de Dijon
Daix, 21121
France
Phone 33 3 80 44 75 00
Fax -

Top Executives

Name Age Since Title
Chris Buyse 57 2017 Independent Director
Sven Francque - - Member of Scientific Advisory Board
Kenneth Cusi - - Member of Scientific Advisory Board
Manal Abdelmalek - - Member of Scientific Advisory Board
Glen Clack - - Member of Scientific Advisory Board
Jean-Louis Junien 77 2016 Chairman of Scientific Advisory Board
Heinz Christoph Maeusli 58 2019 Independent Director
Annick Schwebig 70 2017 Independent Director
Xiaoqin Lu 46 2018 Independent Director
Arun J. Sanyal - 2020 Member of Scientific Advisory Board
Andrew Shenker 67 2019 Member of Scientific Advisory Board
Martine Zimmermann 53 2021 Independent Director
Trever Bivona - 2022 Member of the Scientific Advisory Board
Elisabetta Bugianesi - 2022 Member of the Scientific Advisory Board
Gérard Zalcman - - Scientific Advisory Board Member
Pierre Broqua 62 2011 Co-Founder, Chief Scientific Officer, Deputy CEO & Director
Frederic Cren 58 2011 Co-Founder, CEO & Chairman
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

IVA Comments

Write your thoughts about Inventiva Sa
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email